International Forum of Allergy & Rhinology
Copyright © 2013 ARS-AAOA
Edited By: David W. Kennedy, M.D., University of Pennsylvania
Online ISSN: 2042-6984
Wiley Author Licensing Service (WALS)
For authors signing current journal licensing/copyright agreement
Note to Contributors on Deposit of Accepted Version
Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a repository after an embargo period. Details of funding arrangements are set out at the following website: http://www.wiley.com/go/funderstatement. Please contact the Journal production editor if you have additional funding requirements.
Wiley has arrangements with certain academic institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: http://www.wiley.com/go/funderstatement
If you do not select the OnlineOpen option you will follow the current licensing signing process as described above.
For authors choosing OnlineOpen
If you decide to select the OnlineOpen option, please use the links below to obtain an open access agreement to sign [this will supersede the journal’s usual license agreement]. By selecting the OnlineOpen option you have the choice of the following Creative Commons License open access agreements:
To preview the terms and conditions of these open access agreements please click the license types above and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.
If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with Wellcome Trust and Research Councils UK requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.
For RCUK and Wellcome Trust authors click on the link below to preview the terms and conditions of this license:
Creative Commons Attribution License OAA : Link here
About International Forum of Allergy & Rhinology
International Forum of Allergy & Rhinology is a peer-reviewed scientific journal, and the Official Journal of the American Rhinologic Society and the American Academy of Otolaryngic Allergy, published by John Wiley & Sons, Inc. International Forum of Allergy & Rhinology provides a forum for clinical researchers, basic scientists, clinicians, and others to publish original research and explore controversies in the medical and surgical treatment of patients with otolaryngic allergy, rhinologic, and skull base conditions. The application of current research to the management of otolaryngic allergy, rhinologic, and skull base diseases and the need for further investigation will be highlighted. Unsolicited manuscripts must meet pre-submission requirements.
Material submitted to International Forum of Allergy & Rhinology must be original and not published or submitted for publication elsewhere. Copies of any related in press publications should accompany manuscripts submitted to International Forum of Allergy & Rhinology.
Online Submission Procedure
International Forum of Allergy & Rhinology uses ScholarOne Manuscripts (formerly known as Manuscript Central), a Web-based, peer-review tracking system, for online submission of all manuscripts.
Authors are required to submit the following manuscript information online using ScholarOne Manuscripts:
· corresponding author’s contact information (a valid e-mail address is required)
· manuscript title
· cover letter
Once a manuscript has been submitted online, an e-mail acknowledgment will be sent. Authors can check the status of a manuscript at any time by logging on to ScholarOne Manuscripts.
Format of Manuscript Elements
Manuscripts must be in English with wide (1 inch) margins, typed and double-spaced throughout. Please number pages consecutively, and include the corresponding author's name on each page. Manuscripts should contain each of the following elements in sequence: 1) Title page 2) Abstract 3) Text 4) Acknowledgments 5) References 6) Tables 7) Figure legends. Start each subdivision on a new page. Define unusual abbreviations at the first mention in the text.
Manuscripts should follow the AMA Manual of Style (10th ed.) for grammar, punctuation, and style, and should meet the Uniform Requirements for Manuscripts Submitted to Biomedical Journals established by the ICMJE for general authorship guidelines.
Use generic drug names in the text; use of brand names is optional, and these should be specified in parentheses. The text should be written in a uniform style, and its contents as submitted for consideration should be deemed final by the author and suitable for publication as follows:
Title Page. The title page should contain the complete title of the manuscript, names and affiliations of all authors, institution(s) at which the work was performed, and name, address, telephone and fax numbers, and E-mail address of the author responsible for correspondence. Authors should also provide a short title of not more than 45 characters (including spaces), and must identify a minimum of five key words (5-10), not in the title but taken from Index Medicus, that will highlight the subject matter of the article. Any funding sources for the study (whether financial or in-kind) and any authors’ financial disclosures and conflict of interest should be listed on this page as well as in the cover letter. No financial disclosures should be noted as well.
Abstract. Abstracts must be 250 words or less, and should be intelligible without reference to the text. Abstracts must be organized into four sections: Background, Methods, Results and Conclusions. Purpose of the study should be included in Background and sample sizes must be included in Methods.
References. References should be numbered consecutively according to the order in which they are cited in the text. A reference cited only in a table or figure is numbered within the sequence established by the first mention of that table or figure in the text.
References must be current. Use of references more than 10 years old is discouraged unless they are classic or unique works. Authors must verify all references. The reference list should follow the text of the manuscript. Follow the AMA Manual of Style (10th ed.) for reference formatting and punctuation.
In the reference list, abbreviate names of journals according to MEDLINE/Index Medicus. For five or more authors, list the first three names followed by "et al." Please note the following examples for format and punctuation:
1. Kobler JB, Chang EW, Zeitels SM, et al. Dynamic imaging of vocal fold oscillation with four-dimensional optical coherence tomography. Laryngoscope 2010; 120:1354-1362.
2. Kay AB, Kaplan AP, Bousquet J, et al. Allergy and Allergic Diseases. 2nd ed. Hoboken, NJ: Wiley-Blackwell; 2009.
Chapter in a book
3. Corrigan C. T Cells and Cytokines in Asthma and Allergic Inflammation. In: Kay AB, Kaplan AP, Bousquet J, et al., eds. Allergy and Allergic Diseases. 2nd ed. Hoboken, NJ: Wiley-Blackwell; 2009:48-82.
4. Health on the Net Foundation. Health on the Net Foundation code of conduct (HONcode) for medical and health Web sites. Available at: http://www.hon.ch/HONcode/Conduct.html. Accessed August 26, 2008.
Figures and Illustrations. *Authors are encouraged to submit their figure files in color. There is no charge associated with color figures.*Number figures consecutively according to the order in which they are cited in the text. The figures should immediately follow the tables in the manuscript. Each file must contain a single figure and be named by figure # (i.e., figure 1, figure 2, etc.). Files containing individual panels will not be accepted. Figures must be in TIFF, EPS, or JPG format. Do not embed figures in the manuscript text.
Figures (line art): Electronic Formatting
· Each figure should be saved in a separate file.
· Text/labeling within figures should be in 9 pt Arial font, to ensure readability in print.
· All figures submitted electronically must be saved as TIFF, EPS, or JPG files.
· The following resolutions are required to ensure print quality: 1200 dpi for line art; 300 dpi for halftones/color (CMYK); 600 dpi for combination halftones/color.
The submission of figures that do not conform to journal requirements will cause a delay in publication.
International Forum of Allergy & Rhinologyreserves the right to resize and/or crop photographs to fit the journal’s format where appropriate.
Research Articles. Research articles are generally 3500 words or fewer, exclusive of tables, figures, and references, and include Introduction, Materials and Methods, Results, Discussion, and Conclusion sections conforming to standard scientific reporting style. The introduction should include a succinct summary of the known literature in the area and a rationale for and justification of the purpose of the study and why the experimental question and hypothesis are important or novel. Whenever possible, information on why the study is important for the practicing clinician should be provided. In the Methods and Results sections, detailed information on statistics should be provided such as name of statistical test, whether tests were one- or two-tailed, test used for each set of data, and correction factors, if any, for multiple comparisons. Data and figures should present or reflect standard deviations rather than standard error of means. All significant and relevant non-significant results must include test values, degree(s) of freedom, and probability. The Discussion section should include a clear exposition of the clinical and scientific importance of the study. Articles should strive to highlight the clinical meaning of the constructs and results as opposed to their methodological and mechanistic implications. Conclusions must be clearly justified from the study.
Ask the Experts
‘Ask the Experts’ is an online commentary column which allows the readership to ask questions regarding of the Journal Editorial Board and other leading experts within the field. Submissions should be no more than 250 words but may also include up to 5 references. The submission may not be directed to a particular individual, but rather should be directed to the Editor. The questions must be problem-specific and not patient-specific, and a decision whether to accept a question and to solicit a response will be made based upon the level of interest to the broader rhinology and allergy community. Selected questions and responses will be published in the print version of the Journal.
Specialty Techniques are short articles describing innovative solutions to clinical problems within the field of rhinology and allergy. Practical value to the readership, originality and quality of illustrations (when appropriate) are essential ingredients, and it is recommended that the manuscripts be accompanied by short video or multimedia presentations that will be accessible to the reader, providing additional information through the journal website. Specialty techniques articles are generally limited to no more than 6 double spaced pages and an abstract is not required.
Editorials are usually solicited; however, unsolicited editorials may be considered in some cases. Topics usually relate to the content of an article featured in the issue. Editorials are four to six double-spaced pages in length.
Letters to the Editor
Letters to the Editor are intended as rapid, timely discussion of recent articles published in International Forum of Allergy & Rhinology. Publication is at the discretion of the Editors. Unlike International Forum of Allergy & Rhinologyarticles, Letters to the Editor do not undergo peer review. We therefore do not consider Letters to the Editor to be short International Forum of Allergy & Rhinology articles. Letters to the Editor are not a medium for any of the following:
· Requests for medical advice, consultation, or assistance
· Dissemination of unpublished research data (including figures or tables), hypotheses, or case reports
· Comments that advertise or promote specific commercial interests
· Comments that promote specific political or religious viewpoints
· Comments that are obscene, rude, libelous, or inflammatory
· Comments that are anonymous or written under a pseudonym
· Comments that are not directly relevant to a recent International Forum of Allergy & Rhinology article
· Comments that are incomprehensible or are not written in English
Letters to the Editor should be no longer than 1000 words (including references) and should cite no more than 10 references. Letter to the Editor authors must observe any licenses or copyrights on original material, are entirely responsible for the accuracy of the content, and must disclose any potential conflicts of interest. Submitting authors are required to provide a valid name and email address, which will be published with their Letter. Letters are acknowledged upon receipt, but Letter authors will not be consulted before publication. All submitted Letters become property of the American Rhinologic Society and the American Academy of Otolaryngic Allergy, and may be edited by the editorial office for clarity or length.
Manuscripts that adhere to submission guidelines are initially reviewed by the Editor of International Forum of Allergy & Rhinology. Manuscripts qualifying for peer-review are sent to at least two expert reviewers. The corresponding author will receive all editorial communications regarding the status of the manuscript, revisions, and reviews. All revisions and the dissemination of the reviewers’ comments and other manuscript information to co-authors are the corresponding author’s responsibility.
International Forum of Allergy & Rhinologyrequires all pre-submissions to contain an article outline and abstract for review by the Editors before any unsolicited manuscript can be submitted for peer-review. All pre-submissions that do not contain this information will be returned without review. Please e-mail an abstract, full author list, manuscript length, and information about the author to the Editorial Office for consideration (see Editorial Office contact information below).
Page proofs are received by the corresponding author directly from the publisher (via e-mail) and must be returned within 48 hours of receipt. Make any corrections to the article using Adobe PDF markup tools and e-mail the proof corrections to the contact person provided within 48 hours. It is the corresponding author's responsibility to consult with co-authors regarding the proofs. Substantial author revisions during this stage of production may incur additional costs, which must be borne by the authors. Excessive corrections must be reviewed and authorized by the Editorial Office.
Definition of Authorship
The journal's definition of what qualifies as authorship is based on the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, established by the International Committee of Medical Journal Editors (ICMJE). Authors are those who have contributed to the conception and design of the article, the acquisition of data, or the analysis and interpretation of data, as well as the writing of the article or the revision of its content; and have read and approved the final version of the article before submission.
All listed authors must sign the copyright transfer agreement . In doing so, each author takes public responsibility for the article’s content. No article will be published without a copyright transfer agreement signed by all the listed authors. Failure to submit this form at the time the manuscript is submitted can cause delays in peer-review and publication. The signed copyright transfer agreement should be scanned and submitted as a PDF file along with the manuscript files via ScholarOne Manuscripts (formerly known as Manuscript Central). Copyright transfer agreements should be uploaded as PDF files with their submissions under “supplementary material not for review."
Authors are required to disclose all relevant financial support and potential conflicts of interest in their cover letter, on the title page, and on the copyright transfer agreement form. If there are no financial disclosures from any authors, this should be stated as well. In addition, authors have an ethical responsibility to ensure all research discussed in their work is credible and data are accurate prior to publication. Authors must also clearly identify, within the manuscript, any discussion of investigational or "off-label" use of drugs or medical devices. The authors will be required to submit such disclosures when submitting their manuscript using ScholarOne Manuscripts (formerly known as Manuscript Central).
All others who contributed to the work should be listed under Acknowledgments. This includes people who provided purely technical help, writing assistance, or general support.
All financial support should be clearly acknowledged in the manuscript, as well as any details regarding the role of the funding organization in the creation of the manuscript.
Corresponding Author Responsibilities
The corresponding author is the point of contact for the Editorial Office and Publisher. He or she is responsible for:
· Collecting signed copyright transfer agreements from all authors and submitting these to the Editorial Office with the manuscript.
· Sharing the reviewers’ comments with the other authors and ensuring the requested revisions are made or clearly disputed before resubmitting the manuscript.
· Page proofs. The publisher will e-mail page proofs to the corresponding author. It is up to the corresponding author to share these proofs with the other authors. The corresponding author is responsible for incorporating all the corrections made by the authors and returning the proofs to the publisher within 48 hours.
· Reviewing the cover. The corresponding author of the article featured on the cover of an issue of the Journal will receive PDF files of cover designs from the Editorial Office. He or she may share these designs with the other authors, but the corresponding author is responsible for ensuring any figure/tables/illustrations taken from the article (or supplied specifically for use on the cover) have been reproduced clearly and accurately, and for verifying the accuracy of their use for the Editorial Office.
National Institutes of Health (NIH) Mandate
Wiley-Blackwell will support our authors by posting the accepted version of articles by NIH grant-holders to PubMed Central upon acceptance by the journal. The accepted version is the version that incorporates all amendments made during peer review, but prior to the publisher’s copy-editing and typesetting. This accepted version will be made publicly available 12 months after publication. The NIH mandate applies to all articles based on research that has been wholly or partially funded by the NIH.
NIH authors should be aware that they will receive an e-mail request once Wiley-Blackwell has posted the files of their accepted manuscript to the NIH Manuscript Submission system to approve the upload for display on the PubMed Central system. This is a requirement of their grant/affiliation.
For NIH employees only, we will accept the NIH Publishing Agreement.
Wiley-Blackwell also offers its OnlineOpen and Funded Access services. Upon payment of the OnlineOpen or Funded Access fee, we will deposit the published version of the article into PubMed Central, with public availability in PubMed Central and on the journal’s website immediately upon publication.
All authors are invited to submit potential cover art (photographs and/or illustrations preferred). See the Figures and Illustrations guidelines above for specifications. International Forum of Allergy & Rhinologydoes not guarantee that cover art submitted will be utilized. Cover art may be submitted as "Supplementary Material Not for Review" when submitting the manuscript using ScholarOne Manuscripts. If the figure/table/illustration submitted for use on the cover does not appear in the article, a separate copyright transfer form will be required for the cover art.
Authors are responsible for obtaining written permission from copyright owners to reproduce or adapt any previously published material (including the author’s own work) that appears in the article being submitted to International Forum of Allergy & Rhinology. Authors must obtain written permission from:
1. the holder of any copyrighted material (text, illustrations, tables) used in the manuscript;
2. the administrator of any institution (university, hospital, clinic) mentioned in the manuscript; and
3. actual persons mentioned in the manuscript.
Where permission has been granted, the author should follow any special wording stipulated by the grantor in acknowledging the source of the material. Formal letters granting permission must be included in the manuscript submission package. If the permissions are not received, the manuscript will not be published.
Permission statements must also be obtained from at least one author when citing unpublished data, in press articles, and/or personal communication. In photographs, patients' identities should be masked whenever possible. However, if patients are identifiable, written permission to use the photograph must be obtained from the patient or guardian and submitted with the manuscript. Clearly state in the manuscript that informed consent has been obtained.
Note: It may take six to eight weeks to receive permission from the copyright holder. Please request all permissions as early as possible.
Requests to reprint material published in International Forum of Allergy & Rhinology may be submitted to John Wiley & Sons, Inc. by going to the Wiley Permissions website or submitting a request by fax to the John Wiley & Sons, Inc. Permissions Department: 201-748-6008.
Accepted articles are embargoed from reporting by all media until 12:01 AM EST on the date of online publication. Authors who discuss their work with the media prior to publication must ensure that the media representatives know the embargo policy and the embargo date. Authors arranging their own publicity on their articles are advised to notify the Editorial Office in advance.
Michelle Gadsden, Managing Editor
International Forum of Allergy & Rhinology
John Wiley & Sons, Inc.
111 River Street
Hoboken, NJ 07030
International Forum of Allergy & Rhinology
John Wiley & Sons, Inc.
111 River Street
Hoboken, NJ 07030